Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sulkowski

Showing results (311-320 of 408) with videos related to

Pageof 41
Sort By:
The Journal of Infectious Diseases|May 15, 2020
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune ActivationDonald D Anthony, Mark S Sulkowski, Laura M Smeaton, et al.
Gastroenterology|May 8, 2004
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled studyNezam H Afdhal, Douglas T Dieterich, Paul J Pockros, et al.
AIDS (London, England)|September 24, 2009
Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitutionAshwin Balagopal, Stuart C Ray, Ruben Montes De Oca, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 23, 2023
Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET studyWesam Aleyadeh, Elizabeth C Verna, Hany Elbeshbeshy, et al.
Kidney International Reports|February 19, 2019
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney DiseaseDavid E Bernstein, Albert Tran, Paul Martin, et al.
Journal of Hepatology|October 27, 2010
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patientsMarie-Louise C Vachon, Stephanie H Factor, Andrea D Branch, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 7, 2011
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3Samir R Shah, Keyur Patel, Patrick Marcellin, et al.
Open Forum Infectious Diseases|May 4, 2019
A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS StudyKathleen M Ward, Oluwaseun Falade-Nwulia, Juhi Moon, et al.
Pharmacogenetics and Genomics|September 25, 2013
Predictors of consent to pharmacogenomics testing in the IDEAL studyAlison B Jazwinski, Paul J Clark, Alexander J Thompson, et al.
Hepatology (Baltimore, Md.)|October 5, 2010
Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotypeAlexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Pageof 41

Showing results (311-320 of 408) with videos related to

Sort By:
Pageof 41
The Journal of Infectious Diseases|May 15, 2020
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune ActivationDonald D Anthony, Mark S Sulkowski, Laura M Smeaton, et al.
Gastroenterology|May 8, 2004
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled studyNezam H Afdhal, Douglas T Dieterich, Paul J Pockros, et al.
AIDS (London, England)|September 24, 2009
Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitutionAshwin Balagopal, Stuart C Ray, Ruben Montes De Oca, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 23, 2023
Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET studyWesam Aleyadeh, Elizabeth C Verna, Hany Elbeshbeshy, et al.
Kidney International Reports|February 19, 2019
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney DiseaseDavid E Bernstein, Albert Tran, Paul Martin, et al.
Journal of Hepatology|October 27, 2010
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patientsMarie-Louise C Vachon, Stephanie H Factor, Andrea D Branch, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 7, 2011
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3Samir R Shah, Keyur Patel, Patrick Marcellin, et al.
Open Forum Infectious Diseases|May 4, 2019
A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS StudyKathleen M Ward, Oluwaseun Falade-Nwulia, Juhi Moon, et al.
Pharmacogenetics and Genomics|September 25, 2013
Predictors of consent to pharmacogenomics testing in the IDEAL studyAlison B Jazwinski, Paul J Clark, Alexander J Thompson, et al.
Hepatology (Baltimore, Md.)|October 5, 2010
Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotypeAlexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Pageof 41